HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moliterno, D. J. Articles by Tcheng, J. E. Search for Related Content PubMed PubMed Citation Articles by Moliterno, D. J. Articles by Tcheng, J. E.

EXPEDITED REVIEW

A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention

Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study

David J. Moliterno, MD, FACC^*,*, James B. Hermiller, MD, FACC, Dean J. Kereiakes, MD, FACC, Eric Yow, MS, Robert J. Applegate, MD, FACC^||, Gregory A. Braden, MD, FACC^¶, Eric J. Dippel, MD, FACC^#, Mark I. Furman, MD, FACC^**, Cindy L. Grines, MD, FACC, Neal S. Kleiman, MD, FACC, Glenn N. Levine, MD, FACC, Tift Mann, III, MD, FACC^||||, Ravi N. Nair, MD, FACC^¶¶, Ronald A. Stine, MD, FACC,^##, Steven J. Yacubov, MD, FACC^*** and James E. Tcheng, MD, FACC

^* Departments of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
St. Vincent's Hospital, Indianapolis, Indiana, USA
The Linder Center-Ohio Heart Health Center, Cincinnati, Ohio, USA
Duke Clinical Research Institute, Durham, North Carolina, USA
^|| Wake Forest University, Winston-Salem, North Carolina, USA
^¶ Forsythe Medical Center, Winston-Salem, North Carolina, USA
^# Genesis Medical Center, Davenport, Iowa, USA
^** University of Massachusetts, Worcester, Massachusetts, USA
William Beaumont Hospital, Royal Oak, Michigan, USA
Baylor College of Medicine and the Methodist DeBakey Heart Center, Houston, Texas, USA
VA Medical Center-Houston, Houston, Texas, USA
^|||| Wake Medical Center, Raleigh, North Carolina, USA
^¶¶ University Hospitals-Case Western Reserve University, Cleveland, Ohio, USA
^## Sentara Norfolk General, Norfolk, Virginia, USA
^*** Riverside Methodist Hospital, Columbus, Ohio, USA

^* Reprint requests and correspondence: Dr. David J. Moliterno, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F-25, Cleveland, Ohio 44195.
molited{at}ccf.org

OBJECTIVES: The aim of this study was to discern a target range of anticoagulation for enoxaparin during percutaneous coronary intervention (PCI) as measured by the Rapidpoint ENOX (Pharmanetics Inc., Morrisville, North Carolina), a new point-of-care test.

BACKGROUND: In the U.S., enoxaparin has been used in only a small proportion of PCI procedures, partly because a rapid enoxaparin-specific assay was unavailable.

METHODS: We analyzed data from 445 enrolled patients receiving subcutaneous or intravenous enoxaparin in a prospective, multicenter study. Serial anticoagulation measurements and clinical outcomes were recorded.

RESULTS: The in-hospital composite occurrence of death, myocardial infarction, and urgent target vessel revascularization was 5.4%, and Thrombolysis In Myocardial Infarction (TIMI) major bleeding, minor bleeding, and any reported bleeding occurred in 0.2%, 1.3%, and 7.9% of patients, respectively. No significant association between procedural ENOX times and ischemic events was observed (p = 0.222), although the event rate was 4.0% among those with ENOX times between 250 to 450 s versus 7.2% for those outside this range (p = 0.134). Increasing ENOX time at sheath removal was correlated with any bleeding (p = 0.010) with a 1% increase for every 30-s rise.

CONCLUSIONS: Ischemic events were infrequent, and the rate appeared lowest in the mid-range of ENOX times. Bleeding events increased with increasing ENOX times. These observations, combined with a suggested procedural anti-Xa level of 0.8 to 1.8 IU/ml, translate into a recommended ENOX time range of 250 to 450 s for PCI and <200 to 250 s for sheath removal.

Abbreviations and Acronyms   ACS   acute coronary syndrome   ACT   activated clotting time   FDA   Food and Drug Administration   GP   glycoprotein   IV   intravenous   LMWH   low-molecular-weight heparin   MI   myocardial infarction   PCI   percutaneous coronary intervention   SC   subcutaneous   TIMI   Thrombolysis In Myocardial Infarction   TVR   target vessel revascularization   UFH   unfractionated heparin

This article has been cited by other articles:

				G. Renda, R. Di Pillo, A. D'Alleva, A. Sciartilli, M. Zimarino, E. De Candia, R. Landolfi, G. Di Giammarco, A. Calafiore, and R. De Caterina Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery Haematologica, March 1, 2007; 92(3): 366 - 373. [Abstract] [Full Text] [PDF]

				S. A Spinler, A. K Wittkowsky, E. A Nutescu, and M. A Smythe Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin Ann. Pharmacother., July 1, 2005; 39(7): 1275 - 1285. [Abstract] [Full Text] [PDF]

				F. Andreotti and R. C. Becker Atherothrombotic Disorders: New Insights From Hematology Circulation, April 12, 2005; 111(14): 1855 - 1863. [Full Text] [PDF]

				L. R Moser and J. S Kalus Role of Low-Molecular-Weight Heparin in Invasive Management of Non-ST-Elevation Acute Coronary Syndromes Ann. Pharmacother., December 1, 2004; 38(12): 2094 - 2104. [Abstract] [Full Text] [PDF]

				P. Das and D. J. Moliterno Fractionating Heparins and Their Clinical Trial Data--Something for Everyone JAMA, July 7, 2004; 292(1): 101 - 103. [Full Text] [PDF]